Sanofi beat analyst sales forecasts for the third quarter with stronger than expected turnover for influenza vaccines and robust demand for Dupixent, its anti-inflammatory drug developed with Regeneron Pharmaceuticals Inc. Group sales were €12.48 billion for the quarter which was 5% above the consolidated forecast of the financial community. On a reported basis, this represented an increase of 19.7%. The increase at constant exchange rates was 9%.
